Tumor Markers

TUMOR MARKERS LIST: LABORATORY ELISA TESTS

Tumor markers are substances that are produced by the body in response to cancer or other certain benign (non-cancerous) conditions. These substances can be found in samples of blood, tumor tissue, urine, stool and other bodily fluids of some cancer patients.

Tumor markers are useful in helping to detect, diagnose and manage some types of cancers. The level of tumor marker present can sometimes reflect the stage (extent) of the disease or the patient’s prognosis (the likely outcome or the course of disease) for some types of cancers. Tumor markers can also be periodically measured during any cancer therapy treatment, where a decrease in level or a return to normal level for the marker’s can indicate that the treatment is working and the cancer is responding positively. These markers are also often measured after a treatment has ended in order to check for recurrence (i.e. the return of cancer).

Many different tumor markers have been characterized extensively and used for many clinical applications. Some are found to be associated with only one type of cancer whereas other can be linked to two or more types of cancers. Presently, there is no “universal” tumor marker which has the ability to detect any type of cancer.

Common tumor markers with enzyme activity are prostatic acid phosphatase and prostate specific antigen.

Carcinoembryonic antigen and carbohydrate antigen (CA) 19-9 are the most commonly used markers when it comes to the early diagnosis of cancer. These markers have been used for the prediction of prognosis and recurrences of gastric cancer after surgery. Cancer patients tend to be at a higher risk of infection, so biomarkers that identify disease early can help with the management and treatment and ultimately the everyday life of patients.

Increases in tumor markers can also be a sign of autoimmune disease.

Some of the most common tumor markers and the cancer type that they are used for are listed below:

• Alpha-Fetoprotein (AFP): Liver cancer and germ cell tumor.
• Beta-2-Microglobulin (B2M): Multiple myeloma, some lymphomas and chronic lymphocytic leukemia.
• Beta-Chorionic Gonadotropin (Beta-CG): Choriocarcinoma and germ cell tumors.
• BRCA1 and BRCA2: Ovarian cancer.
• C-Kit/CD117: Mucosal melanoma and gastrointestinal stromal tumor.
• Calcitonin: Medullary thyroid cancer.
• CA15-3/CA27.29: Breast cancer.
• CA19-9: Bile duct cancer, pancreatic cancer, gastric cancer and gallbladder cancer.
• CA-125: Ovarian cancer.
• Carcinoembryonic antigen (CEA): Colorectal cancer.
• Chromogranin A (CgA): Neuroendocrine tumors.
• Cytokeratin fragment 21-1: Lung cancer.
• EGFR: Non-small cell lung cancer.
• Progesterone Receptor (PR)/Estrogen Receptor (ER): Breast cancer.
• Fibrin/Fibrinogen: Bladder cancer.
• Neuron-specific enolase (NSE): Neuroblastoma and small cell lung cancer.
• Prostate-specific antigen (PSA): Prostate cancer.
• Thyroglobulin: Thyroid cancer.

We offers a broad portfolio of tumor markers that can be used for routine diagnostics, clinical research and therapy follow up.

MOST POPULAR TUMOR MARKER ELISA KITS

• Alpha-Fetoprotein (AFP) ELISA Kit
• Calcitonin ELISA Kit
• Carcinoembryonic Antigen (CEA) ELISA Kit
• Beta-2-microglobulin (B2M) ELISA Kit
• Neuron-Specific Enolase (NSE) ELISA Kit
• Total Prostate Specific Antigen (Total PSA) ELISA Kit
• Carcinoma Antigen CA-125 (CA-125) ELISA Kit
• Cytokeratin fragment 21-1 (Cyfra 21-1) ELISA Kit
• Chromogranin A ELISA Kit

REFERENCES

1. Shang X, Song C, Du X, Shao H, Xu D, Wang X. The serum levels of tumor marker CA19-9, CEA, CA72-4, and NSE in type 2 diabetes without malignancy and the relations to the metabolic control. Saudi Med J. 2017;38(2):204-208. doi:10.15537/smj.2017.2.15649
2. Klavins MD, Monoclonal Antibodies to Detect Markers Specific For Tumors, Jamaica NY 11432
3. Faggiano P, D’Aloia A, Brentana L, Bignotti T, Fiorina C, Vizzardi E, Dei Cas L. Serum levels of different tumour markers in patients with chronic heart failure. Eur J Heart Fail. 2005 Jan;7(1):57-61
4. Raeisossadati R, Farshchian M, Ganji A, Tavassoli A, Velayati A, Dadkhah E, Chavoshi S, Mehrabi Bahar M, Memar B, Rajabi Mashhadi MT, Naseh H, Forghanifard MM, Moghbeli M, Moaven O, Abbaszadegan MR. Quantitative analysis of TEM-8 and CEA tumor markers indicating free tumor cells in the peripheral blood of colorectal cancer patients. Int J Colorectal Dis. 2011 Oct;26(10):1265-70. doi: 10.1007/s00384-011-1230-8. Epub 2011 May 15. PMID: 21573768. Germany
5. Meany DL, Sokoll LJ, Chan DW. Early Detection of Cancer: Immunoassays for Blood Plasma Tumor Markers. Expert Opin Med Diagn. 2009;3(6):597-605. doi:10.1517/17530050903266830
6. Whiteside TL. Immune responses to cancer: are they potential biomarkers of prognosis?. Front Oncol. 2013;3:107. Published 2013 May 17. doi:10.3389/fonc.2013.00107. Autoimmunity
7. Nobuyuki Takahashi, Toshio Shimada, Yutaka Ishibashi, Nobuyuki Oyake, Yo Murakami, Transient Elevation of Serum Tumor Markers in a Patient with Hypothyroidism. The American Journal of the Medical Sciences, Volume 333, Issue 6, 2007
8. Riccabona G. Tumormarker in der Endokrinologie (ohne Gynäkologie und Urologie) [Tumor markers in endocrinology (without gynecology and urology)]. Wien Klin Wochenschr. 1989 Jul 14;101(14):479-82. Germany. PMID: 2773484.
9. M Rahman, M Haque, M Mian Tumor Markers: Accuracy and Precision Validity of Statistical Matters of Concern
10. Kim MH, Choi MK. Relationship Between Serum Tumor-related Markers and Dietary Human Nutrition Intakes in Korean Healthy Adults. Clin Nutr Res. 2018;7(3):161-169. doi:10.7762/cnr.2018.7.3.161
11. Kim MH, Choi MK. Relationship Between Serum Tumor-related Markers and Dietary Intakes in Korean Healthy Adults. Clin Nutr Res. 2018 Jul;7(3):161-169. doi: 10.7762/cnr.2018.7.3.161. Epub 2018 Jun 25. PMID: 30079314; PMCID: PMC6073173.